摘要
背景:心脏再灌注损伤会造成毁灭性的后果。组蛋白脱乙酰基酶(HDAC)抑制剂是有效的细胞保护剂,但其在预防心脏损伤中的作用仍不明确。 目的:探讨HDAC抑制剂在体外心肌细胞缺氧-复氧(H/R)模型中的治疗潜力。 方法:对h9c2心肌细胞进行H/R处理,并用5μm等浓度的不同类别特异性和泛HDAC抑制剂进行治疗。用Western blot检测乙酰化组蛋白H3和α-微管蛋白的生物活性,作为浓度适宜性的指标。用甲基噻唑基四氮唑和乳酸脱氢酶分别测定细胞活力和细胞毒性。为了更好地确定最有效的药物tubastatin-a(tub-a)对雷帕霉素(mtor)途径效应器的磷酸肌醇3激酶(pi3k)/哺乳动物靶点和自噬程度的影响,进行了机械学研究。 结果:所有抑制剂均乙酰化了已知的靶蛋白(组蛋白H3和α-微管蛋白),提示浓度足以诱导生物学效应。在暴露于Tub-A的心肌细胞中发现细胞活力提高和细胞毒性降低,而其他HDAC抑制剂的细胞保护作用不一致。PI3K/mTOR通路中的促生存介质上调,经Tub-A处理的细胞自噬程度显著降低。 结论:hdac抑制剂可提高心肌细胞H/R模型的细胞存活率,其Ⅱb类抑制剂(tub-a)具有较好的细胞水平和药效。这种效应至少部分与促生存介质表达增加和自噬程度降低有关。
关键词: 组蛋白脱乙酰酶,组蛋白脱乙酰酶抑制剂,缺氧复氧,缺血再灌注损伤,心脏损伤。
Current Molecular Medicine
Title:Histone Deacetylase Inhibition Attenuates Cardiomyocyte Hypoxia-Reoxygenation Injury
Volume: 18 Issue: 10
关键词: 组蛋白脱乙酰酶,组蛋白脱乙酰酶抑制剂,缺氧复氧,缺血再灌注损伤,心脏损伤。
摘要: Background: Cardiac reperfusion injury can have devastating consequences. Histone deacetylase (HDAC) inhibitors are potent cytoprotective agents, but their role in the prevention of cardiac injury remains ill-defined.
Objective: We sought to determine the therapeutic potential of HDAC inhibitors in an in vitro model of cardiomyocyte hypoxia-reoxygenation (H/R).
Method: H9c2 cardiomyocytes were subjected to H/R and treated with various classspecific and pan-HDAC inhibitors in equal concentrations (5µM). Biological activity of inhibitors was determined, as a proxy for concentration adequacy, by Western blot for acetylated histone H3 and α-tubulin. Cell viability and cytotoxicity were measured by methyl thiazolyl tetrazolium and lactate dehydrogenase assays, respectively. Mechanistic studies were performed to better define the effects of the most effective agent, Tubastatin-A (Tub-A), on the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway effectors, and on the degree of autophagy.
Results: All inhibitors acetylated well-known target proteins (histone H3 and α-tubulin), suggesting that concentrations were adequate to induce a biological effect. Improved cell viability and decreased cell cytotoxicity were noted in cardiomyocytes exposed to Tub-A, whereas the cytoprotective effects of other HDAC inhibitors were inconsistent. Pro-survival mediators in the PI3K/mTOR pathway were up-regulated and the degree of autophagy was significantly attenuated in cells that were treated with Tub-A.
Conclusion: HDAC inhibitors improve cell viability in a model of cardiomyocyte H/R, with Class IIb inhibition (Tub-A) demonstrating superior cellular-level potency and effectiveness. This effect is, at least in part, related to an increased expression of prosurvival mediators and a decreased degree of autophagy.
Export Options
About this article
Cite this article as:
Histone Deacetylase Inhibition Attenuates Cardiomyocyte Hypoxia-Reoxygenation Injury, Current Molecular Medicine 2018; 18 (10) . https://dx.doi.org/10.2174/1566524019666190208102729
DOI https://dx.doi.org/10.2174/1566524019666190208102729 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review
Current Diabetes Reviews The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi
Current Topics in Medicinal Chemistry AMP-Activated Protein Kinase: Structure and Regulation
Current Protein & Peptide Science Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Cardio-Renal-Anemia Syndrome: A Link Between Erythropoietin, Dimethylarginine and Homocysteine
Current Medicinal Chemistry Wave Intensity Analysis in the Human Coronary Circulation in Health and Disease
Current Cardiology Reviews Integrating Pharmacogenetics for Assessment of Herb-Drug Interactions: Has the Time Come?
Current Pharmacogenomics and Personalized Medicine Meet Our Editorial Board Member
Current Medical Imaging Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance
Current Vascular Pharmacology Host Pathways of Hemostasis that Regulate Group A Streptococcus pyogenes Pathogenicity
Current Drug Targets Novel 4-Oxothienopyrimidinyl Propanoic Acid Derivatives as AMPActivated Protein Kinase (AMPK) Activators
Letters in Drug Design & Discovery Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets Effects of Cichorium Intybus Linn on Blood Glucose, Lipid Constituents and Selected Oxidative Stress Parameters in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Resveratrol and Analogues: A Review of Antioxidant Activity and Applications to Human Health
Recent Patents on Food, Nutrition & Agriculture Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Clinical and Molecular Genetic Aspects of Hypertrophic Cardiomyopathy
Current Cardiology Reviews